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Aims Cardiovascular diseases (CVDs) increase mortality risk from coronavirus infection (COVID-19). There are also
concerns that the pandemic has affected supply and demand of acute cardiovascular care. We estimated excess




We used (i) national mortality data for England and Wales to investigate trends in non-COVID-19 and CVD excess
deaths; (ii) routine data from hospitals in England (n = 2), Italy (n = 1), and China (n = 5) to assess indirect pandemic
effects on referral, diagnosis, and treatment services for CVD; and (iii) population-based electronic health records
from 3 862 012 individuals in England to investigate pre- and post-COVID-19 mortality for people with incident
and prevalent CVD. We incorporated pre-COVID-19 risk (by age, sex, and comorbidities), estimated population
COVID-19 prevalence, and estimated relative risk (RR) of mortality in those with CVD and COVID-19 compared
with CVD and non-infected (RR: 1.2, 1.5, 2.0, and 3.0).
Mortality data suggest indirect effects on CVD will be delayed rather than contemporaneous (peak RR 1.14). CVD
service activity decreased by 60–100% compared with pre-pandemic levels in eight hospitals across China, Italy,
and England. In China, activity remained below pre-COVID-19 levels for 2–3 months even after easing lockdown
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and is still reduced in Italy and England. For total CVD (incident and prevalent), at 10% COVID-19 prevalence, we
estimated direct impact of 31 205 and 62 410 excess deaths in England (RR 1.5 and 2.0, respectively), and indirect
effect of 49 932 to 99 865 deaths.
...................................................................................................................................................................................................
Conclusion Supply and demand for CVD services have dramatically reduced across countries with potential for substantial, but
avoidable, excess mortality during and after the pandemic.
                                                                                                                                                                                                                   
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Introduction
Coronavirus disease 2019 (COVID-19) has had unplanned conse-
quences for non-COVID-19 health services. We described reduc-
tions in urgent cancer referrals and chemotherapy compared to pre-
COVID-19 levels.1 Decreases in presentation and treatment of myo-
cardial infarction (MI)2–4 in Italy and the USA suggest effects on care,
but services have not been studied across specific Cardiovascular
diseases (CVDs), countries or different phases of the pandemic.
Early reports from Wuhan, China, demonstrated high prevalence
of and mortality from COVID-19 in individuals with CVD; confirmed
across countries, particularly with coronary heart disease (CHD) and
heart failure (HF).5–8 UK government policy for ‘physical distancing’
in high-risk subgroups for COVID-19, announced on 16 March 2020,
included CVD, especially HF.9 On 22 March 2020, a further 1.5 mil-
lion people in England (with ‘extremely vulnerable’ conditions) were
recommended at least 12 weeks of ‘shielding’,10 excluding those with
CVD, prior to UK lockdown on 23 March.11 Better understanding of
pre- and post-COVID-19 mortality risk across specific CVDs may
help decisions and policies regarding physical isolation.
Therefore, effects of COVID-19 on individuals and health systems
are: (i) direct due to infection, and (ii) indirect due to unprecedented
system strain and associated behaviour changes.12 Those with CVD,
carrying the greatest burden of global morbidity and mortality,13 are
likely to be particularly affected. Beyond direct effects, systematic
examination of recent and longer-term trends for CVD services may
help in planning the timing and nature of exit from lockdown and
strategies for any subsequent infection peaks. Moreover, reductions
in rates of referral, diagnosis, and treatment, may have fatal long-term
consequences, caused by ‘supply’ (e.g. lower healthcare availability)
and/or ‘demand’ (e.g. delayed presentation), but have not been inves-
tigated. Electronic health records (EHRs) have been used in studies
across different specific CVDs,14 and enable novel insights regarding
direct and indirect COVID-19-related excess deaths, across incident
and prevalent CVD, and the spectrum of care.
Objective
We used: (i) national mortality data for England and Wales to investi-
gate trends in non-COVID-19 and CVD excess deaths; (ii) routine
data from hospitals in England, Italy, and China to assess indirect
effects on services for referral, diagnosis, and treatment of CVD dur-
ing the pandemic; and (iii) population-based EHR in England to inves-
tigate pre- and post-COVID-19 mortality by underlying risk factors
for people with incident and prevalent CVD.
Graphical Abstract
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Weekly information on CVD mortality and
emergency attendances in England and
Wales
We obtained weekly cause-specific mortality data (all-cause, COVID,
non-COVID, CVD) for England and Wales from ONS15 and cardiac-
related attendance data from the Emergency Department (ED)
Syndromic Surveillance System for England.16
Monthly referral, diagnosis, and treatment
data for CVD across countries
We obtained data from hospitals in the UK (n = 2; University College
London NHS Trust, and King’s College Hospital London NHS
Foundation Trust); China (n = 5; Wuhan Union Hospital, Zaoyang First
Hospital, Xiangyang First Hospital, Xiantao People’s Hospital, Tianmen
First Hospital); and Italy (n = 1; Ospedale Santa Maria delle Croci,
Ravenna). For all data, weekly or monthly relative risks (RRs) were calcu-
lated, compared with pre-lockdown (3 January). Further details of data
and RR calculations are given in the Supplementary material online,
Methods.
Population-based EHR in England to
estimate pre- and post-COVID mortality
To estimate pre-COVID-19 incidence and mortality in individuals with
CVD and comorbidities, we used EHR across primary care (Clinical
Practice Research Datalink, CPRD-GOLD), hospital care (Hospital
Episodes Statistics, HES), and death registry (Office of National Statistics,
ONS) with prospective recording and follow-up; linked by CPRD and
NHS Digital using unique healthcare identifiers.17 Over 99% of England’s
population is registered with general practice (GP). CPRD is representa-
tive by socio-demography, ethnicity, and overall mortality.18 Eligible indi-
viduals were aged >_30 years, registered with a GP between 1 January
1997 and 1 January 2017 with >_1 year of follow-up. Study entry was
1 year following latest GP registration for each individual, to more com-
pletely capture past medical history. The baseline date for each patient
was the latest of the following: their registration at their general practice,
their general practice ‘up-to-standard’ (UTS) date or their 30th birthday.
Open-access electronic health record phenotypes
We defined non-fatal (alive for >_30 days post-diagnosis) CVD using 16
previously validated CALIBER phenotypes: stable angina, unstable angina,
MI, CHD unspecified, HF, cardiac arrest, transient ischaemic attack, is-
chaemic stroke, stroke unspecified, intracerebral haemorrhage, subarach-
noid haemorrhage, peripheral arterial disease, atrial fibrillation (AF),
abdominal aortic aneurysm, deep vein thrombosis (DVT), and pulmonary
embolism (PE), as per prior studies.14,17,18 We included DVT and PE due
to clinical importance of venous thromboembolism in COVID-19.19
CVD was defined by first CVD record in the study period. Incident and
prevalent disease were with no prior CVD history, and first CVD history,
respectively. Validated phenotype definitions of diseases and COVID-19-
relevant conditions (https://caliberresearch.org/portal)14,17,18 were gen-
erated from hospital and primary care data, using Read clinical termin-
ology (version 2).
We defined 15 comorbidities or comorbidity clusters involving 40 indi-
vidual conditions associated with poor COVID-19 outcomes by UK gov-
ernment guidance.9,10 Further details are in Supplementary material
online, Methods. Multimorbidity was co-occurrence of >_2 of these
conditions.20
Estimating incidence rates and pre-COVID-19 1-year
mortality
We estimated incidence rates per 100 000 person-years and pre-
COVID-19 1-year mortality risk for incident and prevalent CVD using
Kaplan–Meier analyses stratified by specific CVD and number of (non-
CVD) comorbidities (0, 1, 2, and 3þ), scaling up from CALIBER (3.8 mil-
lion individuals) to the whole population of England aged 30þ, consisting
of 35 407 313 individuals (using 2018 estimates of overall population size
and mortality21).
Estimating 1-year direct and indirect excess COVID-19
deaths
Excess deaths were considered direct (due to or with COVID-19 infec-
tion) or indirect (due to changes in health services). Direct excess deaths
were estimated by applying RRs of 1.2, 1.5, 2, and 3 (compared with pre-
COVID-19 mortality rate), based on published hazard ratios for CVD
and COVID-19 deaths,8,22,23 in the absence of CVD cohort studies inves-
tigating all-cause mortality in those with and without infection. We mod-
elled 10% infection rate based on recent seroprevalence estimates,24–25
and included 40% and 80% infection rates, to reflect possible future scen-
arios as the pandemic progresses. Although infection rate will change de-
pending on pandemic phase, we assumed infection rate over 1 year in line
with the first wave.
Based on RRs from ONS data, comparing with the same week average
over the last 5 years [peak RR 1.14, 95% confidence interval (CI) 1.12–
1.16 for excess CVD deaths and 1.32, 95% CI 1.31–1.33 for excess non-
COVID-19 deaths; Figure 1] and likely longer-term effects on CVD mor-
tality, we estimated direct and indirect excess deaths together by applying
RR 1.2–40% (10% infected, 30% affected) and 80% (10% infected, 70%
affected) of the population, respectively. These indirect effects are plaus-
ible, given service changes in CVD observed across countries,2–4 Thus,
we provide low (infection rate 10% and no indirect effect at RR 1.5, 2.0
and 3.0), medium (infection rate 10% and 30% indirectly affected at RR
1.2), and high estimates (infection rate 10% and 70% indirectly affected at
RR 1.2) of excess deaths, projecting to the whole English population
(2018: 35 407 313 individuals aged >_30).21 All analyses were performed
using R (version 3.4.3).
Results
Weekly information on CVD mortality
and emergency attendances in England
and Wales
Non-COVID-19 and CVD-related deaths in England and Wales
increased in the same chronology as total (including COVID-19)
deaths until mid-May 2020 (compared with the same week over the
last 5 years). The peak observed RR for CVD deaths was in the week
ending 24 April (1850 vs. 1626 deaths, RR 1.14) and the lowest in the
week ending 8 May 2020 (1318 vs. 1487 deaths, RR 0.89). The same
trend was present regardless of whether the RR was calculated com-
pared to the average of previous years, or pre-COVID-19 (3 January
2020). Between 6 and 27 March, cardiac ED attendances decreased
in England (minimum RR 0.57) and were had not fully recovered on
15 May, which was after easing of lockdown (Figure 1).
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Monthly referral, diagnosis, and
treatment data for CVD across countries
In China (both Wuhan and other hospitals) and Italy, activity (referral,
diagnosis, and treatment) was significantly reduced compared with
pre-COVID levels. In Wuhan, there was 83.4% reduction in referral,
92% in diagnosis and 99% in treatment levels of MI by the 1 February,
a month after the outbreak started. Corresponding decreases were
92%, 97%, and 87% for stroke; 83%, 93%, and 98% for HF; and 83%,
95%, and 94% for AF. Tianmen and Xiantao demonstrated equivalent
decreases across all four disease services. Although decreases were
relatively less in Zaoyang and Xiangtang, there were 40–80% reduc-
tions across services, except for diagnosis of MI which increased in
Zaoyang between January and March.
Even after easing and stopping of lockdown, Wuhan reported 50–
100% decreases in services for MI, stroke, HF, and AF. In other
Chinese hospitals, activity had mostly returned to pre-COVID levels
by April 2020. Recovery of activity began to occur during the lock-
down period and differed across Chinese hospitals, suggesting pos-
sible differences in infection rates, patient presentation and
behaviour, clinician behaviour and COVID-19-related system strain.
In Italy, decreases ranged from 45% for stroke treatment to 94% for
HF treatment and 100% for AF diagnosis. In England, there was
reduced activity across CVDs during the pandemic. Services in Italy
and England had not reached pre-COVID levels even by the easing of
lockdown. Across countries, referral rates for all diseases and treat-
ment of MI were particularly affected and declines in activity occurred
before the peak of cases or deaths (Figure 2).
Population-based EHR in England to
estimate pre- and post-COVID mortality
Estimating incidence rates and pre-COVID-19 1-year
mortality
Of 3 862 012 individuals in our English cohort, 538 037 had incident
CVD and 580 437 had prevalent CVD. Age-adjusted incidence rates
(per 100 000 population) were highest for AF (330), CHD (261), HF
(168), stable angina (140), and DVT (139) (Supplementary material
online, Figure S1). For incident CVDs, 1-mortality rates varied by spe-
cific CVD: 58.4% for cardiac arrest, 42.1% for intracerebral haemor-
rhage, 30.3% for HF, 20.1% for MI, 12.1% for CHD, and 4.8% for
stable angina. Absolute 1-year mortality was highest for AF
(234 778), HF (173 955), CHD (114 383), and stroke (63 276).
Mortality rates were relatively lower for prevalent CVDs
(Supplementary material online, Figure S2, Results).
Across incident and prevalent CVDs, prevalence of 0, 1, 2, and 3þ
co-morbidities was 26.2% and 27.1%, 33.2%, and 36.3%, 21.9%, and
20.5%, 18.6%, and 16.2%, respectively. Across CVDs, hypertension,
chronic kidney disease (CKD), cancer, chronic obstructive pulmon-
ary disease (COPD), and diabetes were commonest (Supplementary
material online, Table S1, Figure S3). Comorbidity profiles were similar
in those with prevalent CVD (Supplementary material online, Figure
S4). Multimorbidity was associated with increased 1-year mortality,
e.g. in incident AF, 1-year mortality was 31% vs. 9% in men and 34%
vs. 16% in women for >_3 vs. 0 conditions. One-year mortality risks
were >50% in those with incident cardiac arrest or intracerebral
haemorrhage and >_3 conditions (Figures 3B and Supplementary ma-
terial online, Figure S5B).
Estimating 1-year direct and indirect excess COVID-19
deaths
For incident CVD, at 10% infection rate, there would be 5067,
10 135, and 20 269 excess deaths at RR 1.5, 2.0, and 3.0, respectively.
The medium (10% infected, 30% affected) and high (10% infected,
70% affected) estimates were 8112 and 16 225 excess deaths
(Figure 4A).
For prevalent CVD, at 10% infection rate, there would be 26 138,
52 275, and 104 550 excess deaths at RR 1.5, 2.0 and 3.0, respectively.
The medium and high estimates were 41 820 and 83 640 excess
deaths (Figure 5A).
Figure 1 Weekly national data for excess total, non-COVID and cardiovascular deaths in England and Wales, and emergency department cardiac
attendances for England: relative risks.
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For total CVD (incident and prevalent combined), at 10%
infection rate, we estimated a direct effect of 31 205, 62 410, and
124 819 excess deaths at RR, 1.5, 2.0, and 3.0, respectively.
For total CVD, the medium and high estimates were 49 932 and
99 865 excess deaths.
For incident CVD, at 10% COVID-19 rate, we estimated 2508 vs.
1068, 5016 vs. 2136, and 10 033 vs. 4272 excess deaths in multimor-
bidity compared with no comorbidities at RR 1.5, 2.0, and 3.0,
respectively. At medium levels (10% infected, 30% affected), we esti-
mated 4013 vs. 1709 excess deaths; and at high levels (10% infected,
70% affected), we estimated 8026 vs. 3417 excess deaths in multi-
morbidity compared with no comorbidities at corresponding RRs
(Figure 4B). Among those with prevalent CVDs, we estimated higher
excess deaths at 1 year than for incident CVDs with similar associa-
tions with number of comorbidities (Figure 5B).
Discussion
This first analysis from large-scale population-based EHR across 16
specific CVDs and multimorbidity in the COVID-19 context has four
findings. First, profound disruption of CVD services across referral,
diagnosis, and treatment (seen in UK, Italy, and China) may contribute
to excess deaths. Second, there are high rates of ‘high-risk’ and ‘ex-
tremely vulnerable’ conditions among people with CVD, often in
combination, varying by specific CVD. Third, we predict significant
excess deaths in individuals with CVD, over a 1-year time horizon
partly because indirect effects may be delayed. Fourth, excess deaths
in prevalent and incident CVD, by direct and indirect effects, suggest
that access to acute and chronic CVD care should be prioritized dur-
ing future pandemic waves.
Professional organizations quickly produced evidence-based CVD
management guidelines in the COVID-19 context.26 Our analysis
highlights the pandemic’s real and potential impact on CVD health-
care provision in different countries at different stages in their
responses. At peak, almost all CVD healthcare activity collapsed in
Wuhan. Although Italy and the UK were affected later, CVD services
were, and still are, compromised in pre-lockdown and lockdown
phases. Changes in CVD excess deaths have not yet been observed
in ONS data, suggesting that indirect effects may manifest over at
least a year, rather than contemporaneously with activity reductions
observed across countries. Overall, these data emphasize indirect
effects of COVID-19, helping to quantify and model true ‘relative
impact’, and relative contributions of pandemic vs. lockdown on
Figure 2 Hospital activity before and during the COVID-19 pandemic for referral, diagnosis, and treatment of cardiovascular disease in China, Italy
and England.
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..CVD services. We believe countries should monitor near real-time
service activity, and COVID-19 and non-COVID-19 deaths27 over
the coming year to understand and mitigate excess deaths in individu-
als with CVD, especially in those countries still at earlier phases, such
as Brazil.
There is debate about which conditions should be on ‘high-risk’
and ‘extremely vulnerable’ lists of conditions for physical isolation
policies, which should include some CVDs and combinations of
comorbidities, based on our risk estimates and COVID-death data
to-date.6,12 CVD is known to have high prevalence, incidence and
mortality, varying by arterial territory. We now show that AF, CHD,
HF, stable angina, and DVT have the highest pre-COVID-19 inci-
dence rates. Prognosis varies by incident vs. prevalent disease, specific
CVD and number and combination of comorbidities, highlighting
need for individualized risk prediction across CVD. On a different
note, our findings also bring into question the rationale for looking at
composite endpoints such as ‘MACE’ (major adverse cardiovascular
events) in trials and other studies due to highly variable risk across
specific CVD.28
In individuals with CVD at 10% population infection rate, there
would be 50 937 excess deaths at RR 1.5, with higher rates at higher
infection rates. An earlier lockdown, as in New Zealand or the Indian
state of Kerala, minimizes overall deaths. Conversely, in countries
such as the UK and USA, delayed lockdown may exacerbate direct
and indirect effects of COVID-19, supported by rising non-COVID-
19 deaths in ONS data. COVID-19 and non-COVID-19 deaths can
be avoided by: (i) acting early and reducing infection rates by wide-
spread testing, stringent physical isolation and suppression policies,
and (ii) focusing on the preventable CVD burden. For example, HF,
MI, ischaemic stroke, and AF are prevalent conditions with highest
mortality rates; all with evidence-based therapies. The same is true
for common CVD comorbidities, which often occur in clusters:
hypertension, CKD, cancer, COPD, and diabetes, underlining import-
ance of integrated CVD and risk factor management pre- and post-
COVID-19.
Our findings may have implications for which aspects of health
services (acute vs. chronic, treatment vs. prevention, across specific
CVDs) require attention at different pandemic phases.28 Demand for
NCD care is documented in humanitarian emergencies,29 but NCD
surveillance is absent in pandemic preparedness, planning and
responses, particularly in low- to middle-income countries,13 where
our findings will be magnified. The learning health system concept,30
where near real-time data inform science, evidence and care, has not
been used optimally during the COVID-19 pandemic, but our CVD
referral, diagnosis, and treatment data show that data need not be
complex.
Figure 2 Continued.
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Our study uses large-scale, nationally representative EHR with vali-
dated definitions across a comprehensive list of specific CVDs and
comorbidities. We present real-time service data from three coun-
tries. There are several limitations. In the UK, our study population
was 5% of the overall population. We do not have country-level data
outside the UK. Our analyses of risk and excess deaths use retro-
spective EHR data. Our model assumes static infection rate and RR,
does not include changes over time, and uses peak RR estimates. The
estimated impact of COVID-19 may vary depending on the assumed
RR (Supplementary material online, Discussion). We used service data
from limited hospitals and only UK (ONS) administrative data was
available. We do not report primary care or community level data
regarding CVD services. We modelled using limited comorbidities
and simple multimorbidity counts, and did not study impact of ethni-
city. We assumed the same effect across all specific CVDs.
Conclusion
There is a substantial avoidable burden of excess mortality in peo-
ple with CVD during the COVID-19 pandemic. Excess CVD
deaths can be reduced in more integrated approaches, focused on
reducing COVID-19 infection rates, as well as managing CVD and
comorbidities.
Figure 3 COVID-19 relevant comorbidities in incident cardiovascular diseases in England. (A) Proportion of individuals with 0, 1, 2, and 3þ comor-
bidities by specific CVD. (B) One-year mortality in individuals with 0, 1, 2, and 3þ comorbidities by specific CVD.
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